Surface Oncology - SURF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.07
▼ -0.01 (-0.93%)
Get New Surface Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SURF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SURF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Surface Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.07.

This chart shows the closing price for SURF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Surface Oncology. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/20/2023WedbushDowngradeOutperform ➝ NeutralLow
6/20/2023Robert W. BairdDowngradeOutperform ➝ NeutralLow
6/20/2023HC WainwrightDowngradeBuy ➝ NeutralLow
3/10/2023WedbushReiterated RatingOutperform$3.00Low
3/10/2023HC WainwrightReiterated RatingBuy$6.00Low
11/3/2022BTIG ResearchLower Target$12.00 ➝ $6.00Low
11/3/2022WedbushLower Target$12.00 ➝ $3.00Low
11/3/2022Robert W. BairdLower Target$11.00 ➝ $6.00Low
11/3/2022HC WainwrightLower TargetBuy$8.50 ➝ $6.00Low
8/8/2022HC WainwrightLower TargetBuy$10.00 ➝ $8.50Low
6/5/2022JonestradingReiterated RatingBuy$12.00High
4/13/2022JonestradingReiterated RatingBuy$12.00Low
3/3/2022HC WainwrightReiterated RatingBuy$10.00High
9/19/2021BTIG ResearchReiterated RatingBuy$17.00High
8/9/2021BTIG ResearchReiterated RatingBuy$17.00Low
6/4/2021JonestradingReiterated RatingBuy$18.00High
5/17/2021BTIG ResearchInitiated CoverageBuy$17.00High
4/11/2021JonestradingReiterated RatingBuy$18.00High
3/22/2021Robert W. BairdReiterated RatingBuy$14.00Medium
12/18/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $15.00High
9/4/2020HC WainwrightInitiated CoverageBuy$11.00High
8/27/2020WedbushInitiated CoverageOutperform$12.00High
6/11/2020CowenReiterated RatingMarket Perform ➝ AverageHigh
6/8/2020Evercore ISIReiterated RatingOutperform ➝ Market Perform$9.00High
11/13/2019CowenReiterated RatingBuyHigh
5/9/2019CowenReiterated RatingBuyMedium
(Data available from 4/21/2019 forward)

News Sentiment Rating

-0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
11/22/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/22/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
2/20/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
3/21/2024
  • 2 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 9 very negative mentions
4/20/2024

Current Sentiment

  • 2 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 9 very negative mentions

Recent Stories by Sentiment

Surface Oncology logo
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.
Read More

Today's Range

Now: $1.07
Low: $1.01
High: $1.09

50 Day Range

MA: $1.01
Low: $0.88
High: $1.08

52 Week Range

Now: $1.07
Low: $0.56
High: $1.43

Volume

1,510,100 shs

Average Volume

430,375 shs

Market Capitalization

$65.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Surface Oncology?

The following Wall Street sell-side analysts have issued research reports on Surface Oncology in the last twelve months: HC Wainwright, Robert W. Baird, and Wedbush.
View the latest analyst ratings for SURF.

What is the current price target for Surface Oncology?

0 Wall Street analysts have set twelve-month price targets for Surface Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Surface Oncology in the next year.
View the latest price targets for SURF.

What is the current consensus analyst rating for Surface Oncology?

Surface Oncology currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SURF, but not buy more shares or sell existing shares.
View the latest ratings for SURF.

What other companies compete with Surface Oncology?

How do I contact Surface Oncology's investor relations team?

Surface Oncology's physical mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 714-4096 and its investor relations email address is [email protected]. The official website for Surface Oncology is www.surfaceoncology.com. Learn More about contacing Surface Oncology investor relations.